EDITORIAL
B-type natriuretic peptide: a role in selection and follow up of the implantable cardioverter-defibrillator patient?
Correspondence to:
Correspondence to:
Dr Mark Anderson
The Cardiac Centre, Morriston Hospital, Swansea SA6 6NL, UK; mark.anderson{at}sinus-rhythm.com
B-type natriuretic peptide may have a role in predicting the risk of ICD therapy, identifying patients with deteriorating clinical status and allowing them to be selected for more detailed medical review and, if necessary, drug treatment
Abbreviations: ANP, atrial natriuretic peptide; BNP, B-type natriuretic peptide; CAD, coronary artery disease; CHF, congestive heart failure; CNP, C-type natriuretic peptide; ICD, implantable cardioverter-defibrillator; LV, left ventricular; LVEF, left ventricular ejection fraction; NICM, non-ischaemic cardiomyopathy; NYHA, New York Heart Association
Keywords: B-type natriuretic peptide; BNP; implantable cardioverter-defibrillator; ICD
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
